Ultragenyx Pharmaceutical Inc.RARE
ASignal's systematic analysis rates RARE as Neutral.
Reflects the latest available analysis · analyzed Aug 20, 2026
The case on RARE
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong revenue growth (28.1% YoY)
- High growth score (0.9)
- Positive MACD histogram indicating potential trend stabilization
- Current ratio above 1.5 suggests short-term liquidity adequacy
- Negative gross, operating, and net margins
- Negative free cash flow and operating cash flow
- Negative price momentum and trading below SMA20 and SMA50
- High EV/EBITDA ratio with negative EBITDA
- Negative return on assets
- No Reddit mentions indicating low retail sentiment visibility
See the full verdict on RARE
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes RARE
Most investors never get a second opinion, let alone several. ASignal runs RARE past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.